Trial Profile

Phase II study of multi-agent chemotherapy in patients with adult precursor T acute lymphoblastic leukemia.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelarabine (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Mercaptopurine; Methotrexate; Prednisolone; Vincristine
Indications Precursor cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

01 Feb 2025 Results assessing effectiveness and safety of nelarabine (NEL)-combined chemotherapy for newly diagnosed adult T-cell, published in the Cancer Science.
07 Jul 2013 Planned end date (2 Jun 2020) added as reported by University Hospital Medical Information Network - Japan.
07 Jul 2013 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com